TY - CHAP M1 - Book, Section TI - Immunosuppressive and Immunomodulatory Drugs A1 - Kurtzman, Drew A1 - Vleugels, Ruth Ann A1 - Callen, Jeffrey A2 - Kang, Sewon A2 - Amagai, Masayuki A2 - Bruckner, Anna L. A2 - Enk, Alexander H. A2 - Margolis, David J. A2 - McMichael, Amy J. A2 - Orringer, Jeffrey S. PY - 2019 T2 - Fitzpatrick's Dermatology, 9e AB - AT-A-GLANCEImmunosuppressants and immunomodulators represent an indispensable group of antiinflammatory medications that are capable of treating a wide array of inflammatory skin conditions.The immunosuppressive and immunomodulatory drugs covered in this chapter include mycophenolate mofetil, the calcineurin inhibitors (cyclosporine, tacrolimus, and pimecrolimus), and the mammalian target of rapamycin (mTOR) inhibitor everolimus.The primary goal of therapy with immunosuppressants and immunomodulators is to effectively treat an inflammatory condition while maintaining patient safety.By working in an additive or synergistic fashion, combination regimens have the potential for greater efficacy and may allow for decreased doses of individual drugs, which may enhance overall safety and reduce medication-related side effects.A comprehensive understanding of the pathophysiology of the disease being treated as well as the pharmacokinetic and pharmacodynamic properties of each immunosuppressant and immunomodulator is fundamental to favorable patient outcomes. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/12 UR - accessmedicine.mhmedical.com/content.aspx?aid=1161344743 ER -